Literature DB >> 10757410

'Gangliocytomas' of the pituitary: a heterogeneous group of lesions with differing histogenesis.

J F Geddes1, G H Jansen, S F Robinson, E Gömöri, J L Holton, J P Monson, G M Besser, T Révész.   

Abstract

Hamartomatous or neoplastic ganglion cells in the sella turcica are an unusual cause of symptoms. They have been reported in association with a functioning or nonfunctioning pituitary adenoma, with pituitary cell hyperplasia, and occasionally as masses unassociated with an adenoma, again with variable endocrinologic findings. Fewer than 50 cases of intrasellar ganglion cell lesions have been reported in the literature, only six of them associated with Cushing's syndrome. We describe the clinicopathologic features of another eight patients, three of whom presented with acromegaly, four with apparently nonfunctioning adenohypophyseal masses, and one with Cushing's syndrome. On histology, six of them were found to have sparsely granulated growth hormone (GH)-producing adenomas with ganglion cell areas, one appeared to have a gangliocytoma not associated with an adenoma, whereas the eighth had a ganglion cell lesion in the posterior pituitary. The morphologic and immunohistochemical findings suggest that the ganglion cell component of seven of these tumors has resulted from neuronal differentiation in a GH-producing adenoma, despite the lack of demonstrable adenoma in one case. A true sellar "gangliocytoma" or hamartoma of ectopic hypothalamic-type neurons appears to be a rarer explanation for the presence of ganglion cells in a pituitary biopsy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757410     DOI: 10.1097/00000478-200004000-00017

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature.

Authors:  Ping Xiao; Ling Xue; Jian-Jun Peng; Shi-Ting Feng; Bing Liao; Jian-Ming Wen
Journal:  BMJ Case Rep       Date:  2009-04-07

Review 2.  Infrasellar pituitary gangliocytoma causing Cushing's syndrome.

Authors:  Marie-Eve Domingue; Etienne Marbaix; Jean-Luc Do Rego; Vincent Col; Christian Raftopoulos; Thierry Duprez; Hubert Vaudry; Dominique Maiter
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma.

Authors:  M L Isidro; P Iglesias Díaz; X Matías-Guiu; F Cordido
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

4.  Pituitary adenoma with gangliocytic component: report of 5 cases with focus on immunoprofile of gangliocytic component.

Authors:  Serdar Balci; Arzu Saglam; Hakan Oruckaptan; Tomris Erbas; Figen Soylemezoglu
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

5.  Acromegaly associated with gangliocytoma.

Authors:  R K Crowley; Y Al-Derazi; K Lynch; D Rawluk; C J Thompson; M Farrell; A Agha
Journal:  Ir J Med Sci       Date:  2009-09-30       Impact factor: 1.568

6.  Rare sellar region tumors.

Authors:  D J Halbauer; I Mészáros; T Dóczi; Pál Kajtár; László Pajor; K Kovács; Eva Gömöri
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

Review 7.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

8.  Ganglioglioma of the neurohypophysis.

Authors:  B W Scheithauer; A I Silva; J E Parisi; K Kovacs; E Horvath
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  An unusual association of a sellar gangliocytoma with a prolactinoma.

Authors:  Omar Serri; France Berthelet; Manon Bélair; Sophie Vallette; Sylvia L Asa
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Combined gangliocytoma and prolactinoma of the pituitary gland.

Authors:  Shuji Mikami; Kaori Kameyama; Satoshi Takahashi; Kazunari Yoshida; Takeshi Kawase; Toshiaki Sano; Makio Mukai
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.